Anixa Biosciences (NASDAQ:ANIX) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research report report published on Tuesday,Benzinga reports. They currently have a $7.00 target price on the stock.

Several other brokerages also recently commented on ANIX. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a report on Wednesday, January 22nd. Maxim Group assumed coverage on shares of Anixa Biosciences in a report on Friday, March 21st. They issued a “buy” rating and a $10.00 price target for the company.

Anixa Biosciences Trading Down 1.6 %

ANIX stock opened at $3.15 on Tuesday. The firm’s 50-day moving average is $2.94 and its two-hundred day moving average is $3.00. The company has a market capitalization of $101.42 million, a price-to-earnings ratio of -8.08 and a beta of 0.86. Anixa Biosciences has a 52 week low of $2.07 and a 52 week high of $4.20.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Tuesday, March 11th. The company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). On average, equities research analysts predict that Anixa Biosciences will post -0.41 earnings per share for the current year.

Insider Transactions at Anixa Biosciences

In other Anixa Biosciences news, CEO Amit Kumar acquired 43,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were acquired at an average price of $2.23 per share, with a total value of $95,890.00. Following the purchase, the chief executive officer now owns 559,925 shares of the company’s stock, valued at $1,248,632.75. This represents a 8.32 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Lewis H. Titterton, Jr. bought 10,000 shares of Anixa Biosciences stock in a transaction on Friday, January 17th. The shares were acquired at an average price of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the acquisition, the director now owns 922,334 shares of the company’s stock, valued at approximately $2,370,398.38. This represents a 1.10 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 75,289 shares of company stock worth $177,021. 25.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Anixa Biosciences

Hedge funds have recently modified their holdings of the business. Millennium Management LLC bought a new stake in Anixa Biosciences during the 4th quarter worth approximately $26,000. Virtu Financial LLC acquired a new position in shares of Anixa Biosciences in the third quarter valued at approximately $34,000. Renaissance Technologies LLC increased its position in shares of Anixa Biosciences by 36.5% during the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock worth $34,000 after acquiring an additional 3,900 shares in the last quarter. Prosperity Wealth Management Inc. acquired a new stake in shares of Anixa Biosciences during the fourth quarter worth $54,000. Finally, Jane Street Group LLC bought a new stake in Anixa Biosciences in the 4th quarter valued at $67,000. Institutional investors and hedge funds own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.